New Delhi, Aug. 6 -- Divi's Laboratories Ltd, India's second-largest pharmaceutical company by market capitalization, is expected to report a 14-18% jump in revenue and robust margin expansion for the quarter ended 30 June.

BNP Paribas and Kotak Securities peg the contract development and manufacturing firm's first-quarter revenue growth at 18% year-on-year, while Nuvama expectsit to be 14%. Profit after tax is expected to grow 34% on-year, according to Nuvama.

The company's custom synthesis portfolio is expected to see continued traction with 23% on-year growth in the April-June quarter, according to Kotak. Its generic active pharmaceutical ingredients (API) business is seen growing at 13% on-year but declining 4% from the preceding th...